GlassScriptPhysician profile
Stephanie Hull
NPI 1700130598
$10,421.51
in general payments reported to CMS, 2019-2025
37 companies · $2,825 in 2025
The $2,825 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,212 · 2022: $1,655 · 2023: $2,268 · 2024: $2,462 · 2025: $2,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,381 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,380.75 |
| Education | $174.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,081.37 | 2021-2025 | |
| Gilead Sciences, INC. | $1,179.36 | 2021-2025 | Livdelzi, Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,108.62 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $993.06 | 2021-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $606.99 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $479.43 | 2021-2024 | Trulance, Xifaxan |
| Ardelyx, INC. | $458.63 | 2022-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $370.91 | 2021-2025 | Terlivaz |
| Pfizer INC. | $310.07 | 2021-2025 | |
| Madrigal Pharmaceuticals | $271.61 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $245.69 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $233.72 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $228.41 | 2021-2024 | Sucraid, Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.46 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $211.57 | 2021-2024 | Linzess |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $201.01 | 2023-2025 | Omvoh |
| Genzyme Corporation | $155.43 | 2022-2025 | |
| Celltrion USA INC. | $140.64 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $112.66 | 2022-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $82.47 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $76.32 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $76.30 | 2022-2025 | Rebyota |
| Exact Sciences Corporation | $72.51 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $68.91 | 2022 | |
| Redhill Biopharma INC. | $55.63 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $55.28 | 2024 | Iqirvo |
| Fresenius Kabi USA, LLC | $52.18 | 2023 | Idacio |
| Orphalan INC | $44.33 | 2024 | Cuvrior |
| Fujifilm Healthcare Americas Corporation | $43.32 | 2024-2025 | Utaswako Afp-L3 |
| Sandoz INC. | $39.62 | 2023 | Hyrimoz |
| Braintree Laboratories, INC. | $34.87 | 2025 | Suflave, Sutab |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2023 | Imfinzi |
| Ultragenyx Pharmaceutical INC. | $22.31 | 2025 | Dojolvi |
| Biocon Biologics INC | $20.51 | 2025 | Yesintek |
| Mirum Pharmaceuticals, INC. | $18.80 | 2024 | Livmarli |
| Evoke Pharma, INC. | $18.12 | 2024 | |
| Boston Scientific Corporation | $8.46 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.